News Release

November 1, 2024

JCR Pharmaceuticals Co., Ltd.

Notice Regarding the Result and Completion of Repurchase of Own Shares through Off-Auction Own Share Repurchase Trading System (ToSTNeT-3)

Hyogo, Japan, November 1, 2024 -- JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; "JCR") announced today that the Company conducted and completed a repurchase of its own shares, announced on October 30 and 31, 2024, as follows.

1. Reason for the repurchase

To improve capital efficiency and enhance its flexible capital strategy that may correspond to the changes in the business environment.

2. Details of share repurchase

(1) Class of share repurchased: Common stock of the Company
(2) Total number of shares repurchased: 3,672,000 shares
(3) Total amount of repurchase: 2,530,008,000 yen
(4) Date of repurchase: November 1, 2024
(5) Method of share repurchase: Purchase through the Off-Auction own share repurchase trading system (ToSTNeT-3) of the Tokyo Stock Exchange

(Reference)

Details of resolution regarding repurchase of own shares (announced on October 30 and 31, 2024)

Class of share to be repurchased: common stock of the Company
Total number of shares to be repurchased: 3,750,000 shares (at maximum)
(2.98% of the total number of shares of common stock outstanding excluding treasury shares)
Total amount of repurchase: 2,583,750,000 yen (at maximum)

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 49-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values – reliability, confidence, and persistence – benefit all our stakeholders, including employees, partners, and patients. For more information, please visit https://www.jcrpharm.co.jp/en/site/en/.

Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as "believe," "estimate," "anticipate," "intend," "plan," "will," "would," "target" and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but are not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors' pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions.

This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue.

Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.

Contact:
Investors & Media:
JCR Pharmaceuticals Co., Ltd.
Corporate Communications
ir-info@jp.jcrpharm.com

###